FG-M108 plus chemo for Claudin18.2-positive pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new targeted drug (FG-M108) combined with standard chemotherapy, compared to chemotherapy alone, for people with advanced pancreatic cancer that has not been treated before. It is for those whose tumors have a specific protein (Claudin18.2) that the drug is designed to attack.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of pancreatic cancer called adenocarcinoma that cannot be removed by surgery or has spread to other parts of the body.
- You cannot have received any previous chemotherapy or other anti-cancer treatment for advanced pancreatic cancer.
- At least 40% of your cancer cells must show a specific protein called Claudin18.2, which will be checked by a lab.
- You must be able to do your daily activities without much help (ECOG score 0 or 1).
- You cannot have other serious illnesses, such as uncontrolled heart disease, active infections, or another cancer in the last 3 years.
- You must not be pregnant or breastfeeding, and must follow contraception rules if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests a new medicine (IN10018) and a specific added antibody (KN046) together with standard chemotherapy for advanced pancreatic cancer. It aims to see whether this combination can better control the cancer and how safely it can be given.
This trial tests a new drug, LM-302, combined with gemcitabine for people with a specific type of advanced pancreatic cancer that has not responded to or stopped working on first-line treatment. The goal is to see if the combination is safe and effective.
This trial tests a new drug called ANO31905 added to standard chemotherapy for people with advanced pancreatic cancer that has a specific protein called CLDN18.2 on its cells. The study aims to see if the combination works better than chemo alone.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This trial tests a new treatment called QLS31905 plus chemotherapy against a placebo plus chemotherapy for people with advanced pancreatic cancer that hasn't been treated yet. It aims to see if the new combination works better.
This trial tests AK104 (an antibody medicine) given with standard chemotherapy as the first treatment for advanced pancreatic ductal cancer. It aims to see whether this combination works better and is safe for people with cancer that has spread or is advanced.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.